I'm Tired of Hearing 'The Disposable Duodenoscope Is Too Expensive'
I'll say it bluntly: If you're a hospital system or a large surgery center, and you're still only evaluating the Boston Scientific disposable duodenoscope based on unit cost, you're probably ignoring the real math. I've been in this industry long enough to see it happen over and over.
In my role coordinating medical device procurement for emergency response teams, I've handled maybe 50-plus rush orders for replacement scopes after a reprocessing failure—or, worse, a confirmed contamination event. Around 40 of those. I'd have to check the logs. The point is: I've seen the chaos that a 'saved' $500 on a reusable scope can cause. Let me explain why I think the disposable duodenoscope isn't just a cost center—it's a risk management tool that many underappreciate.
The Argument Against Disposables (Which I Think Is Simplified)
The standard procurement argument goes like this: 'A reusable duodenoscope costs $X per reprocessing cycle. A disposable like the Boston Scientific EXALT Model-D costs $Y per unit. Over 50 uses, the reusable is always cheaper.' And on paper, that's true.
It's tempting to think you can just compare those per-procedure costs. But identical specs from different vendors (or different models) can result in wildly different outcomes when you factor in a failure. The 'always buy the cheapest per-use option' advice ignores the transaction cost of managing a potential infection outbreak, which is something I've seen happen twice in my career. That's not a hypothetical cost. It's a real, budget-destroying event.
Here's What the Spreadsheet Misses
1. The Cost of 'Almost' a Failure
Most procurement teams look at reprocessing failure rates—say, 1–2%—and think, 'That's acceptable.' But I've sat in the room where a reprocessing tech runs a culture test that comes back positive on an endoscope. Not a clinical infection, just a positive swab. The scope is pulled. The schedule for three procedures is blown. A surgeon is waiting. A patient is already prepped.
Now, what's the cost? You don't just pay for the disposable replacement. You pay for the OR downtime, the rescheduling, the surgeon's frustration, and the admin time to scramble for a replacement. I saw this happen in March 2024. A colleague needed a sterile scope 36 hours before a complicated ERCP. The normal reprocessing vendor had a 'quality hold' on a batch. We ended up ordering a single EXALT Model-D from a regional distributor, paid $850 extra in expedited shipping (on top of the $1,200 base cost), and delivered it for the procedure. The client's alternative was cancelling and losing a $14,000 OR block. The 'cheaper' reusable wasn't cheap that day.
2. The Cardiac Monitor Lesson: Same Idea, Different Machine
Think about it—this isn't unique to endoscopy. Look at a cardiac monitor. You can buy a top-tier system for $20,000, or you can lease a more basic but reliable monitor for a specific unit. Most large hospitals will buy the expensive one and amortize it. But for a small clinic running a weekend event? They need a cardiac monitor that works, now. They don't need a 10-year asset. They need a tool for the job.
The same logic applies to the duodenoscope. The argument that 'Boston Scientific is selling an overpriced piece of plastic' ignores the context. For a high-risk patient, for a difficult anatomy, for a location where reprocessing is inconsistent, that single-use device is worth a huge premium. It's not about the price of the plastic. It's about the price of the certainty it provides.
3. Small Orders, Big Problems
This ties into something that frustrates me about procurement culture. When I'm triaging a rush order for a single disposable duodenoscope, I often get pushback: 'Can't you just wait for the bulk order?' No. No, I can't.
When I was starting out, the vendors who treated my $200 orders seriously are the ones I still use for $20,000 orders. Small doesn't mean unimportant—it means potential. A hospital system that won't buy one disposable to test it out is a system that's stuck in a mindset. The same goes for the fundus camera market, or dental chair components. If you're a small clinic, and you need to evaluate a fundus camera for a specific diabetic retinopathy screening event, you should be able to order a single unit. The procurement mindset that says 'minimum order of 10' is hostile to innovation and to good patient care.
But What About the Reprocessing Risk?
I know what the defenders of the reusable model will say: 'Modern reprocessing is safe. The FDA has cleared these protocols. The EXALT Model-D is a solution for the 1% case, not the standard.'
Look, I can only speak to my experience coordinating emergency replacements. If you're a massive hospital with a perfect reprocessing team and zero compliance incidents, more power to you. But 'perfect' is a rare situation. (Should mention: I've seen the reprocessing logs from five different facilities. The compliance rate is rarely 100%). The disposable duodenoscope isn't a replacement for the reusable fleet. It's a backup. It's a risk-management tool for when the 'cheaper' option fails. And if your risk management budget doesn't include that $1,200 device, you're probably gambling somewhere else.
My Verdict? Evaluate It. Seriously.
So, what to look for in evaluating the EXALT Model-D? Look at your own data. Don't just compare per-procedure costs. Compare your actual, documented failure rate. Look at the cost of a single cancelled procedure. Look at the potential cost of an infection lawsuit (and yes, those happen). Then, try buying one from a distributor—don't commit to a full contract. This is classic 'test before you invest.'
Don't dismiss the disposable duodenoscope as a marketing gimmick from Boston Scientific. It's a tool with a specific job. And for the right job, it's not a luxury—it's a necessity. Small doesn't mean unimportant. And single-use doesn't mean wasteful when it prevents a bigger failure.
As of January 2025, the pricing and availability of the EXALT Model-D may vary. Verify current pricing with your Boston Scientific representative.